2型糖尿病合并非酒精性脂肪肝患者血浆同型半胱氨酸水平变化及临床意义
被引量：2
摘要
研究显示同型半胱氨酸（Hcy）水平升高是动脉粥样硬化性血管病变的独立危险因素[1,2],而Hcy主要在肝脏进行合成和分解,其中85%的Hcy转硫作用都在肝脏中进行,因此肝脏是Hcy的重要调节器官,本文旨在研究2型糖尿病合并非酒精性脂肪性肝（NAFL）患者空腹血浆Hcy水平的变化,并对相关影响因素加以分析以探讨其临床意义.
出处
《中国药物与临床》
CAS
2011年第5期578-580,共3页
Chinese Remedies & Clinics
参考文献10
-
1Schindhelm PK,Dekker JM,Nijpels G,et al.Alanine aminotransferase predicts coronary heart disease events:a 10-year follow-up of the Hoorn study.Atherosclerosis,2007,191(2):391-396.
-
2吴锦丹,马建华,叶飞,李倩,刘好,齐绍康.高同型半胱氨酸血症与2型糖尿病冠心病[J].中华内分泌代谢杂志,2004,20(1):36-38. 被引量：36
-
3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1516
-
4牛春峰,王新春,于汉力,许红丽.血清同型半胱氨酸浓度与冠心病相互关系的研究[J].中国危重病急救医学,2001,13(3):153-155. 被引量：15
-
5Day C,Saksena S.Nonalcoholic steatohepatitis:definitions and pathogensis.J Gastroenterol Hepatol,2002,17(6):377-384.
-
6范建高,郑晓英,张梅,杨兆瑞.非酒精性脂肪性肝病大鼠肝窦超微结构及微血栓观察[J].肝脏,2005,10(1):41-42. 被引量：18
-
7Zhou RH,Shi Q,Gao HQ,et al.Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population.J Atheroscler Thromb,2001,8:30-32.
-
8Perreault M,Marette A.Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle.Nat Med,2001,7(10):1138-1143.
-
9Pou S,Pou WS,Bredt DS,et al.Generation of superoxide by punified brain nitric oxide synthase.J Biol Chem,1992,267:24173-24176.
-
10石胜,陈健勇,黄华兴,卢岑.血浆同型半胱氨酸水平与肝硬化严重程度的相关性研究[J].实用医学杂志,2004,20(5):530-531. 被引量：19
二级参考文献34
-
1范建高,郑晓英,张梅,曹中伟,丁晓东.非酒精性脂肪性肝病大鼠肝脏纤溶酶原激活物及其抑制物mRNA表达[J].肝脏,2004,9(2):103-105. 被引量：6
-
2胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量：108
-
3Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia - an emerging and important risk factor for thromboembolic and cardiovascular disease.AM J Clin Pathol, 1996, 106(6):709-722
-
4Houseton PE, Rana S, Sekhsaria S, et al. Homocysteine in sickle cell disease: relationship to stroke. AM J Med, 1997, 103(3):192- 196
-
5Graham TM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA, 1997, 277(22):1775 - 1781
-
6Mayer EL, Jacobsen DM, Robinson K. Homocysteine and coronary atheroselcrosis. JACC, 1996, 27(3) :517 - 527
-
7Stead LM, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat liver. Biochem J, 2000, 350(3) :685 - 692
-
8Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension, 2001, 38(5): 1217 - 1221
-
9Tsai M Y，Atherosclerosis，1996年，122卷，6977页
-
10Wanless LR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis. Hepatology, 1995,21:1232-1237.
共引文献1584
-
1昭日格图,其布日,鲍明明,娜日苏,领小,Jun Ai.富含硅的天然矿泉水降血脂活性研究[J].内蒙古石油化工,2020(8):15-19. 被引量：1
-
2施正君,陆玲玉.51例青年脂肪肝患病情况与危险因素分析[J].医学信息（医学与计算机应用）,2014,0(21):248-249. 被引量：1
-
3陈芝芸,严茂祥,何蓓晖.山楂叶总黄酮防治非酒精性脂肪性肝炎的研究[J].浙江中医药大学学报,2007,31(6):686-689. 被引量：14
-
4庞敏,冯丽英.脂联素在非酒精性脂肪肝病中的作用[J].中国全科医学,2008,11(24):2277-2279. 被引量：4
-
5杨明,吴政.老年人非酒精性脂肪性肝病与颈动脉硬化关系的探讨(附96例分析)[J].福建医药杂志,2008,30(6):51-52.
-
6吴佳玉,江南,黄仁刚.当飞利肝宁治疗非酒精性脂肪性肝炎的临床研究[J].四川省卫生管理干部学院学报,2008,27(3):192-193. 被引量：5
-
7潘丰满,张德新,黄江荣.柴胡疏肝散治疗非酒精性脂肪肝82例[J].长江大学学报（自科版）（下旬）,2008,5(4):35-36. 被引量：4
-
8成军,徐道振.双环醇保肝的基础与临床研究进展[J].中华实验和临床感染病杂志（电子版）,2008,2(4):354-358. 被引量：3
-
9詹雨林,李国航,骆欢.慢性肝病患者血清γ-谷氨酰转移酶测定的临床意义[J].中国实用医药,2007,2(25):42-43. 被引量：3
-
10殷红伟,朱丽群.二甲双胍治疗非酒精性脂肪肝的临床观察[J].中国实用医药,2007,2(35). 被引量：8
同被引文献43
-
1FAN J G, FARRELL G C. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009,50( 1 ) :204-210.
-
2LEITE N C, SALLES G F, ARAUJO A L, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in pa- tients with type- 2 diabetes mellitus [ J ]. Liver Int, 2009,29 (1) :113-119.
-
3GUPTA R, BHANGOO A, MATTHEWS N A, et al. The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children [J]. J Pediatr Endocrinol Metab, 2011,24( 11 - 12) :907-911.
-
4AMARAPURKAR D N, HASHIMOTO E, LESMANA L A, et al. How common is non-alcoholic fatty liver disease in the A-sia-Pacific region and are there local differences? [ J]. J Gastroenterol Hepatol, 2007,22 (6) :788- 793.
-
5LU H, ZENG L, LIANG B, et al. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease[J]. Arch Med Res,2009,40(7) :571-575.
-
6ANGULO P. GI epidemiology:nonaleoholie fatty liver disease [ J ]. Aliment Pharmacol Ther, 2007,25 ( 8 ) : 883- 889.
-
7FAN J G, SAIBARA T, CHITTURI S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in A- sia- Pacific? [ J ]. J Gastroenterol Hepatol, 2007,22 ( 6 ) : 794- 800.
-
8SHIRAI K. Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese [ J]. Nihon Rinsho,2001,59 (3) :578-585.
-
9CHOUDHURY J, SANYAL A J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease[ J]. Clin Liver Dis, 2004,8 ( 3 ) : 575- 594, ix.
-
10PASCHOS P, PALETAS K. Non alcoholic fatty liver disease and metabolic syndrome [ J ]. Hippokratia, 2009, 13 ( 1 ) : 9-19.
二级引证文献3
-
1周鸣清,曹永熙,陈欣然,王强.口服碳水化合物激活PI3K/Akt通路改善大鼠术后胰岛素抵抗[J].现代医学,2016,44(6):767-771. 被引量：3
-
2王鲁伃.沙格列汀治疗初发型2型糖尿病合并非酒精性脂肪肝的疗效分析[J].中国实用医药,2020,15(5):126-127. 被引量：4
-
3柴秋琰,田亭,沈超,张梦婷,管晴,王洁.非酒精性脂肪性肝病患者的代谢紊乱特征比较及鉴别方法分析[J].现代医学,2023,51(7):912-917. 被引量：3
-
1许德军,李太平,付菊平.慢性病毒性肝炎前白蛋白、转铁蛋白的检测及临床意义[J].河南医药信息,1999,7(3):25-26. 被引量：2
-
2薛锋,薛明明.AMPK在动脉粥样硬化中的作用[J].疾病监测与控制,2016,10(2):120-122. 被引量：2
-
3黄红革,杨华.2型糖尿病合并非酒精性脂肪肝病患者同型半胱氨酸与胱抑素C的相关性研究[J].山西医药杂志（下半月）,2013,42(3):325-326. 被引量：8
-
4殷军社,崔立.肝炎肝硬化患者血浆同型半胱氨酸水平分析[J].临床荟萃,2008,23(5):332-333. 被引量：1
-
5翁伟安,陈勇毅.柴苓茵郁汤治疗非酒精性脂肪肝32例观察[J].浙江中医杂志,2016,51(8):578-578.
-
6于帅,王斌,杜娜,刘营,王颜刚.非酒精性脂肪肝患者并发2型糖尿病的风险分析[J].山东医药,2015,55(3):50-52. 被引量：11
-
7张宗超.二甲双胍联合硫普罗宁治疗43例非酒精性脂肪性肝患者的疗效观察[J].中外医学研究,2012,10(36):13-14. 被引量：3
-
8刘继花,冯琦赟.中西医结合治疗非酒精性脂肪性肝病72例临床观察[J].医学理论与实践,2012,25(15):1861-1863. 被引量：4
-
9方健强,黄宁生,邱琦,欧华军.阿托伐他汀治疗非酒精性脂肪性肝病观察[J].医学理论与实践,2012,25(19):2376-2377.
-
10臧恒佳.孩子胖更易得肝病[J].健康世界,2015,0(2):8-8.
